Group 4 Created with Sketch.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play All
21 Subscribers
Share Path Report
rss rss .
PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support spe… Continue Reading >>
PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes. << Show Less
Featured Audio
Lucia M. Novak, MSN, ANP-BC, BC-ADM, CDTC - The Art of Medicine: Creating Treatment Regimens With GLP-1 RAs to Reduce Cardiovascular Risks in Patients With T2DM Go online to PeerView.com/SVU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) describes shared decision-making strategies to individualize treatment and reduce cardiovascular risks in patients with T2DM using GLP-1 receptor agonists (GLP-1 RAs). Upon completion of this activity, participants should be better able to: Review the role of, current guidance, and approved indications for GLP-1 RAs in the management of T2DM, Describe the difference between primary and secondary prevention of cardiovascular events and the mechanism(s) proposed for GLP-1 RAs that may reduce cardiovascular risks in patients with T2DM, Evaluate the benefits and risks of GLP-1 RAs based on results from recent clinical trials, especially in terms of primary and secondary cardiovascular prevention, Integrate GLP-1 RAs, as appropriate and using shared decision-making, into the care of patients with T2DM.
Newest Audio
George L. Bakris, MD - Show Me the Data: Improving Renal Outcomes With Glucose-Lowering Therapy in the Individualized Management of T2DM Go online to PeerView.com/RBT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in cardiometabolic health discusses the role and ability of SGLT2 inhibitors to improve renal outcomes in patients with T2DM and/or CKD. Upon completion of this activity, participants should be better able to: Outline the mechanism(s) of action and clinical potential of newer options in glucose-lowering therapy that have been shown to improve renal outcomes in patients with T2DM, Evaluate the clinical efficacy and safety of newer options in glucose-lowering therapy in patients with T2DM and/or CKD, Integrate newer glucose-lowering therapies to improve the management of patients with T2DM and/or CKD based on the latest clinical evidence.
Roger J. Packer, MD - Progressive Pathways: Recent Recommendations and Emerging Therapies for Treating NF1-Associated Tumors Go online to PeerView.com/AGQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF1) is an incurable genetic disorder that primarily gives rise to nervous system tumors but can also lead to multisystem involvement. Neurofibromas are a key feature of NF1, and approximately 50% of patients will develop plexiform neurofibromas (PNs), which are associated with substantial morbidity and carry the potential to transform into malignant peripheral nerve sheath tumors. Optimal care of children with NF1 and NF1-related plexiform tumors includes awareness of the disease biology and the most recent clinical data on innovative therapies for managing the disease. Recent therapeutic developments for NF1 have been tumor-directed, often leveraging agents developed for the treatment of a variety of cancers. Notably, inhibitors of the MAPK signaling pathway, such as MEK inhibitors, offer rational therapeutic options for patients with NF1. This web broadcast features an expert review of treatment recommendations, current management paradigms, and challenges in the care of NF1 and NF1-associated tumors in children, as well as insight into the expanding landscape of targeted therapies and guidance on effectively incorporating these strategies into patient care. Upon completion of this activity, participants should be better able to: Describe fundamental aspects of NF1 etiology, pathophysiology, and clinical presentation as they relate to pediatric patients, Summarize current recommendations for NF1 diagnosis and treatment of NF1-associated tumors in pediatric patients, Evaluate recent evidence regarding the role of emerging therapies in the treatment of NF1-associated tumors in pediatric patients, including agents that affect the RAS/MAPK pathway, Assess options for patient-centered treatment of PNs and other NF1-associated tumors in pediatric patients.
Gwen A. Huitt, MD, MS - Addressing Challenges in the Treatment of Nontuberculous Mycobacterial Lung Disease: Managing Adverse Effects to Keep Patients on Therapy Go online to PeerView.com/SVG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in NTM-LD discusses diagnosing and treating a patient with NTM-LD, with the goal of maintaining treatment adherence. Upon completion of this activity, participants should be better able to: Describe the burden of treatment associated with nontuberculous mycobacterial lung disease (NTM-LD), especially adverse events that may lead to patient discontinuation of therapy, Discuss the latest evidence-based recommendations for the treatment of NTM-LD, including airway clearance, medication optimization, susceptibility testing, repeated cultures, and duration of treatment, Develop treatment plans for patients with NTM-LD based on the latest ATS/IDSA guidelines, disease severity, patient needs and preferences, and the latest clinical evidence on efficacy and safety, Apply strategies to manage adverse events associated with treatment of NTM-LD in order to maintain patient adherence to therapy and improve outcomes.
Matthew T. Ballo, MD, FACR - Modernizing Your Radiation Oncology Practice With Tumor Treating Fields and Other Novel Multimodal Strategies: Understanding the Science, Evidence, and Practical Aspects Across a Range of Solid Tumors Go online to PeerView.com/KGF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies are revolutionizing the therapeutic management of solid tumors. This new modality of alternating electric fields therapy is FDA approved in GBM and MPM and is paving the way for improved outcomes in other solid tumors. As this previously unrecognized antimitotic therapy with a unique mode of delivery continues to be combined with conventional cancer therapies, including surgery, systemic therapy, and radiation therapy, the oncology community will benefit from understanding the practical implications in the multidisciplinary management of cancer. This activity will feature a review of the cutting-edge advancements in cancer devices, as well as expert insights and case discussions on the appropriate care strategies for patients being treated with new modalities like TTFields therapy. And, the expert panel will review key safety and efficacy evidence on innovative and emerging multimodal strategies for the treatment of GBM, MPM, NSCLC, pancreatic cancer, and other GI and gynecologic tumors. Upon completion of this activity, participants should be better able to: Summarize the mechanistic rationale for the use of novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy, Evaluate the key safety and efficacy evidence on innovative strategies available for the therapeutic management of GBM and MPM, Review the most recent evidence and ongoing clinical trials on novel therapeutic modalities, including combining TTFields with systemic therapy, radiotherapy, or other modalities, in multiple tumor types such as lung, pancreatic, gastric, liver, and ovarian cancers, across different treatment settings, Develop strategies to effectively integrate novel technologies into the therapeutic management of patients with cancer, including through appropriate adverse event management and enrollment in clinical trials.
Stephen V. Liu, MD / Bhavesh Shah, RPh, BCOP - Immunotherapy in the Treatment Arsenal for Small Cell Lung Cancer, and Managed Care Implications for the "Four Ps": Patient, Provider, Pharmacy, and Plan Go online to PeerView.com/TMR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology and managed care provide a foundational overview of the mechanism of action of cancer immunotherapies and why this class of agents is different from other oncologic therapies. The panel also explores how immunotherapies have revolutionized the management of cancer over the last few years, particularly the ways in which SCLC management is finally changing. Additionally, the latest research and practical considerations for value assessment of cancer immunotherapies in managed care settings are presented, with specific implications for SCLC. Upon completion of this activity, participants will be able to: Describe the rationale for and potential benefits of integrating immunotherapies and immune-based combination approaches into the SCLC treatment arsenal throughout the disease continuum, Review efficacy and safety findings from key clinical trials assessing immunotherapies and combination approaches across different treatment settings of SCLC, as well as data on potential biomarkers, Incorporate immunotherapies into treatment plans for appropriate patients with SCLC in managed care settings.
J. Fernando Arevalo, MD, PhD, FACS - Seeing the Importance of the Timely Recognition and Treatment of Diabetic Retinopathy and Diabetic Macular Edema Go online to PeerView.com/EVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this case-based activity, an expert ophthalmologist and expert endocrinologist discuss the importance of diagnosing patients with diabetic retinopathy with or without diabetic macular edema early and how individualizing treatment improves outcomes. After participating in this activity, the learner will demonstrate the ability to: Describe current evidence-based recommendations for screening, diagnosis, and treatment of patients with suspected DR with or without DME, Facilitate timely diagnosis and treatment initiation, as appropriate, for patients with DR with or without DME, Incorporate strategies that overcome barriers to ensure timely and appropriate referral to ophthalmologic specialists who can utilize treatment regimens that have been shown to improve outcomes and/or encourage regression of DR in patients with diabetes.
Victor C. Urrutia, MD, FAHA - Not So FAST: Improving the Diagnosis and Treatment of Posterior Circulation Stroke Go online to PeerView.com/NZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert neurologist discusses strategies for accurately diagnosing and treating patients with posterior circulation stroke. After participating in this activity, the learner will demonstrate the ability to: Differentiate the signs and symptoms of acute ischemic posterior circulation stroke from other conditions with which it might be confused, Perform stroke assessments that facilitate more rapid diagnosis of acute ischemic posterior circulation stroke, Compare the therapeutic characteristics of current and emerging thrombolytic agents for acute ischemic stroke.
David F. McDermott, MD - How I Think, How I Treat: Individualizing RCC Therapy in the Era of Immuno-Oncology Go online to PeerView.com/TKZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With new developments in the advanced renal cell carcinoma (RCC) treatment landscape, clinicians have more opportunities for personalizing therapeutic approaches for patients with RCC. Validation of novel combinatorial approaches, such as dual checkpoint inhibition and immunotherapy plus targeted agents, have led to FDA approvals, and novel approaches synergistically combining checkpoint inhibition with targeted therapy have expanded frontline treatment options for patients with advanced disease. This program features the latest research on the efficacy and safety of these newer treatment approaches and expert guidance on selecting and managing the overlapping and non-overlapping adverse events associated with potent immune-based and targeted therapy treatment options. Upon completion of this activity, participants sould be better able to: Identify the latest efficacy and safety findings on new treatment approaches, such as immune checkpoint inhibitors, targeted tyrosine kinase inhibitors, and novel and emerging combination approaches, for advanced and/or resectable renal cell carcinoma (RCC), Choose appropriate, personalized treatment regimens that make use of immune and targeted therapies for patients with advanced RCC in the first-line setting based on pertinent patient- and disease-related characteristics, Integrate novel components into treatment plans over multiple lines of therapy for patients with previously-treated advanced RCC taking into account patient treatment history and comorbidities, Assess treatment-related adverse events in patients with RCC receiving immunotherapy and targeted agents.
Lucia M. Novak, MSN, ANP-BC, BC-ADM, CDTC - The Art of Medicine: Creating Treatment Regimens With GLP-1 RAs to Reduce Cardiovascular Risks in Patients With T2DM Go online to PeerView.com/SVU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) describes shared decision-making strategies to individualize treatment and reduce cardiovascular risks in patients with T2DM using GLP-1 receptor agonists (GLP-1 RAs). Upon completion of this activity, participants should be better able to: Review the role of, current guidance, and approved indications for GLP-1 RAs in the management of T2DM, Describe the difference between primary and secondary prevention of cardiovascular events and the mechanism(s) proposed for GLP-1 RAs that may reduce cardiovascular risks in patients with T2DM, Evaluate the benefits and risks of GLP-1 RAs based on results from recent clinical trials, especially in terms of primary and secondary cardiovascular prevention, Integrate GLP-1 RAs, as appropriate and using shared decision-making, into the care of patients with T2DM.
Load More Audio